JAK inhibition as a therapeutic strategy for immune and inflammatory diseases | Nature Reviews Drug Discovery
Resistance to second-generation androgen receptor antagonists in prostate cancer | Nature Reviews Urology
Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors | Scientific Reports
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer | Nature Reviews Cancer
Frontiers | Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
Mechanisms of resistance to CYP17 inhibitors. Androgen receptor (AR)... | Download Scientific Diagram
CYP17 inhibition as a hormonal strategy for prostate cancer | Nature Reviews Urology
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001 | Nature
CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents | Nature Reviews Urology
Evidence-based capacity of natural cytochrome enzyme inhibitors to increase the effectivity of antineoplastic drugs | SpringerLink
CYP17 inhibitors for prostate cancer therapy - ScienceDirect
Computation | Free Full-Text | Exploring the Chemical Space of Cytochrome P450 Inhibitors Using Integrated Physicochemical Parameters, Drug Efficiency Metrics and Decision Tree Models
CYP17 inhibitors for prostate cancer therapy - ScienceDirect
Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer | Oncogene
Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors | Scientific Reports
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials | Signal Transduction and Targeted Therapy
Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses | Arteriosclerosis, Thrombosis, and Vascular Biology
CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer | British Journal of Cancer
APExBIO - Abiraterone|Potent CYP17 inhibitor|CAS# 154229-19-3
Molecules | Free Full-Text | Enzyme Activity of Natural Products on Cytochrome P450
Biased cytochrome P450-mediated metabolism via small-molecule ligands binding P450 oxidoreductase | Nature Communications
Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer | Scientific Reports
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials | Signal Transduction and Targeted Therapy
Inhibition of cytochrome P450 3A by acetoxylated analogues of resveratrol in in vitro and in silico models | Scientific Reports
